CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies
CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/24/9531 |
| id |
doaj-b9b0b812d1cf4dd98abf70b4427b8225 |
|---|---|
| record_format |
Article |
| spelling |
doaj-b9b0b812d1cf4dd98abf70b4427b82252020-12-16T00:00:50ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-12-01219531953110.3390/ijms21249531CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal AntibodiesMalgorzata Bobrowicz0Matylda Kubacz1Aleksander Slusarczyk2Magdalena Winiarska3Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, PolandDepartment of Immunology, Medical University of Warsaw, 02-097 Warsaw, PolandDepartment of Immunology, Medical University of Warsaw, 02-097 Warsaw, PolandDepartment of Immunology, Medical University of Warsaw, 02-097 Warsaw, PolandCD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and targeting this molecule may provide additional benefit to relapsed or refractory patients. In this review, we aimed to provide an extensive overview of the function of CD37 in B cell malignancies, providing a comprehensive view of recent therapeutic advances targeting CD37 and delineating future perspectives.https://www.mdpi.com/1422-0067/21/24/9531CD37tetraspaninnon-Hodgkin lymphomachronic lymphocytic leukemiaimmunotherapymonoclonal antibodies |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Malgorzata Bobrowicz Matylda Kubacz Aleksander Slusarczyk Magdalena Winiarska |
| spellingShingle |
Malgorzata Bobrowicz Matylda Kubacz Aleksander Slusarczyk Magdalena Winiarska CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies International Journal of Molecular Sciences CD37 tetraspanin non-Hodgkin lymphoma chronic lymphocytic leukemia immunotherapy monoclonal antibodies |
| author_facet |
Malgorzata Bobrowicz Matylda Kubacz Aleksander Slusarczyk Magdalena Winiarska |
| author_sort |
Malgorzata Bobrowicz |
| title |
CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies |
| title_short |
CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies |
| title_full |
CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies |
| title_fullStr |
CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies |
| title_full_unstemmed |
CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies |
| title_sort |
cd37 in b cell derived tumors—more than just a docking point for monoclonal antibodies |
| publisher |
MDPI AG |
| series |
International Journal of Molecular Sciences |
| issn |
1661-6596 1422-0067 |
| publishDate |
2020-12-01 |
| description |
CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and targeting this molecule may provide additional benefit to relapsed or refractory patients. In this review, we aimed to provide an extensive overview of the function of CD37 in B cell malignancies, providing a comprehensive view of recent therapeutic advances targeting CD37 and delineating future perspectives. |
| topic |
CD37 tetraspanin non-Hodgkin lymphoma chronic lymphocytic leukemia immunotherapy monoclonal antibodies |
| url |
https://www.mdpi.com/1422-0067/21/24/9531 |
| work_keys_str_mv |
AT malgorzatabobrowicz cd37inbcellderivedtumorsmorethanjustadockingpointformonoclonalantibodies AT matyldakubacz cd37inbcellderivedtumorsmorethanjustadockingpointformonoclonalantibodies AT aleksanderslusarczyk cd37inbcellderivedtumorsmorethanjustadockingpointformonoclonalantibodies AT magdalenawiniarska cd37inbcellderivedtumorsmorethanjustadockingpointformonoclonalantibodies |
| _version_ |
1724381998847361024 |